T. J. Lynch, D. W. Bell, R. Sordella, et al., “Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib,” New England Journal of Medicine, Vol. 350, No. 21, 2004, pp. 2129-2139.
 F. A. Shepherd, J. R. Pereira, T. Ciuleanu, E. H. Tan, V. Hirsh, S. Thongprasert, et al., “Erlotinib in Previously Treated Non-Small-Cell Lung Cancer,” New England Journal of Medicine, Vol. 353, 2005, pp. 123-132. doi:10.1056/NEJMoa050753
 M. Shiota, S. Nakamura, R. Ichinohasama, et al., “Anaplastic Large Cell Lymphomas Expressing the Novel Chimeric Protein p80NPM/ALK: A Distinct Clinicopathologic Entity,” Blood, Vol. 86, No. 5, 1995, pp. 1954-1960.
 J. Cools, I. Wlodarska, R. Somers, et al., “Identification of Novel Fusion Partners of ALK, the Anaplastic Lymphoma Kinase, in Anaplastic Large-Cell Lymphoma and Inflammatory Myofibroblastic Tumour,” Genes Chromosomes Cancer, Vol. 34, No. 4, 2002, pp. 354-362.
 K. Inamura, K. Takeuchi, Y. Togashi, et al., “EML4-ALK Lung Cancers Are Characterized by Rare Other Mutations, a TTF-1 Cell Lineage, an Acinar Histology, and Young Onset,” Modern Pathology, Vol. 22, No. 4, 2009, pp. 508-515. doi:10.1038/modpathol.2009.2
 D. W. Wong, E. L. Leung, K. K. So, et al., “The EML4-ALK Fusion Gene Is Involved in Various Histologic Types of Lung Cancers from Non-Smokers with Wild-Type EGFR and KRAS,” Cancer, Vol. 115, No. 8, 2009, pp. 1723-1733. doi:10.1002/cncr.24181
 A. T. Shaw, B. Y. Yeap, M. Mino-Kenudson, et al., “Clinical Features and Outcome of Patients with NonSmall-Cell Lung Cancer Who Harbor EML4-ALK,” Journal of Clinical Oncology, Vol. 27, No. 26, 2009, pp. 4247-4253. doi:10.1200/JCO.2009.22.6993
 T. Takahashi, M. Sonobe, M. Kobayashi, et al., “Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4-ALK Fusion Gene,” Annals of Surgical Oncology, Vol. 17, No. 3, 2010, pp. 889-897.
 A. T. Shaw, B. Y. Yeap, B. J. Solomon, et al., “Effect of Crizotinib on Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Harbouring ALK Gene Rearrangement: A Retrospective Analysis,” Lancet Oncology, Vol. 12, No. 11, 2011, pp. 1004-1012.
 H. Shigematsu, L. Lin, T. Takahashi, et al., “Clinical and Biological Features Associated with Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers,” Journal of the National Cancer Institute, Vol. 97, No. 5, 2005, pp. 339-346. doi:10.1093/jnci/dji055
 R. Rosell, T. Moran, C. Queralt, et al., “Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer,” New England Journal of Medicine, Vol. 361, 2009, pp. 958-967. doi:10.1056/ NEJMoa0904554
 M. P. Martelli, G. Sozzi, L. Hernandez, et al., “EML4-ALK Rearrangement in Non-Small-Cell Lung Cancer and Non-Tumor Lung Tissues,” American Journal of Pathology, Vol. 174, No. 2, 2009, pp. 661-670.
 S. J. Rodig, M. Mino-Kenudson, S. Dacic, et al., “Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population,” Clinical Cancer Research, Vol. 15, No. 16, 2009, pp. 5216-5223.